Amgen 133: Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Participants With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Bariatrics

Status:

Recruiting

ClinicalTrials.gov:

NCT05669599

The study aims to compare and assess the dose response of 3 selected doses of AMG 133 compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or obesity without diabetes mellitus (Cohort A) and in participants with overweight or obesity with diabetes mellitus (Cohort B).

Condition

Type 2 Diabetes Mellitus

Keywords

Obesity | Overweight